17 apr: FOCUS: Food Processors To Benefit From Cheaper Grain Prices
17 apr: UPDATE: Marathon Oil: Angola's Block 31 To Start Product..
17-04-2012 21:04:00

2nd UPDATE:Top Court Sides With Generic Drug Makers In Tactics Case

Relateret indhold
31 okt - 
Fredagens aktier: Bank of Japan bankede C20 tilbage mod..
31 okt - 
Aktier/middag: På vej mod forsigtigt punktum på solid u..
31 okt - 
Aktier/åbning: TDC stiger sammen med resten af C20
Relateret debat
31 okt - 
Så er kursen på vej i +
31 okt - 
Det er nok det.... I hvert fald har han overtrådt de be..
31 okt - 
Som jeg skrev solgte jeg på SL minus 3% og nogle andre ..

--Justices give generics new legal tool against brand rivals

--Sun unit wins case, calls ruling important for generic drug makers

--Case involved Novo Nordisk patent for diabetes drug Prandin

(Updates with comment from Novo in 12th paragraph, additional background.)

By Brent Kendall

Of DOW JONES NEWSWIRES

WASHINGTON -(Dow Jones)- The U.S. Supreme Court handed a victory to generic drug companies Tuesday, ruling they can file certain legal counterclaims against brand-drug companies in an effort to get their cheaper copycat medicines on the market.

The court, in an opinion written by Justice Elena Kagan, ruled unanimously that generic drug makers should be allowed to challenge the way brand-name manufacturers describe their patents to the Food and Drug Administration.

The decision overturned an appeals court ruling that said generic makers can't bring those legal claims against brand rivals.

The generics argued that their brand rivals, if left unchecked, can describe their patents broadly in FDA submissions as a way to shut out possible generic competition, even for unpatented uses of a drug. The Obama administration supported those arguments.

Brand drug companies said allowing the counterclaims could lead to costly litigation and undermine patent protection for innovative drugs that are costly to develop.

The controversy arises when the FDA considers a drug maker's application to market a generic drug. As part of that process, the agency considers whether the proposed generic will infringe a branded drug's patents. To determine infringement, the FDA relies on use codes submitted by brand companies that describe the scope of their patents. The agency does not independently verify the accuracy of companies' patent submissions.

As Kagan noted, "the breadth of the use code may make the difference between approval and denial of a generic company's application."

At issue was an appeal by Caraco Pharmaceutical Laboratories, a unit of Sun Pharmaceutical Industries Ltd. (524715.BY), which is seeking to introduce a generic version of Novo Nordisk A/S's (NVO, NOVO-B.KO) diabetes drug Prandin.

One Novo Nordisk patent on the drug compound has expired, but the company holds a second patent, which doesn't expire until 2018, that involves the use of the drug in combination with another medicine.

The FDA has approved three uses for the drug. Caraco wants to introduce a generic version for the uses that aren't patented. The company said it couldn't do so because Novo Nordisk's description of its patent to the FDA was so broad that it foreclosed the agency from approving a generic version of the drug.

A Sun representative called Tuesday's ruling "a very important victory" for the company and the generic industry as a whole.

Novo said its FDA submission is correct. "We are confident that further proceedings will show Caraco's challenge to the use code narrative is meritless," James Shehan, general counsel of Novo's U.S. subsidiary, said in a statement.

In a related dispute, the two companies are fighting over the validity of the Novo patent, which a Michigan federal judge invalidated last year. That case is on appeal.

The case is Caraco Pharmaceutical Laboratories v. Novo Nordisk, 10-844.

-By Brent Kendall, Dow Jones Newswires; 202-862-9222; brent.kendall@dowjones.com

(END) Dow Jones Newswires

April 17, 2012 15:04 ET (19:04 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
30 okt
NOVO-B
Fyføj glemte aktiemarkering :(   Go'e gamle Novo. Du får mange ord med på vejen. Her er lidt fra nog..
8
28 okt
NOVO-B
God pointe.   Omkring cafe-penge, så hober de sig op.   Har altid haft en indædt aversion mod at gå ..
7
30 okt
NOVO-B
i henhold til dansk jantelov og misundelse skulle jeg jo "svine" dig til nu Evald - men tværtimod - ..
5
30 okt
NOVO-B
Hej alle, også til min gode ven Boris !    Med Roling Stones i øregangene kan jeg ikke lade være med..
5
29 okt
NOVO-B
Borisz er en helt!Han bliver ALDRIG liggende og venter på at blive talt ud!Oppe på 7 - senest.Groggy..
4
29 okt
NOVO-B
Endelig en dag med penge på kontoen!! Det jeg har mistet i NOVO har jeg i dag tjent ind og mere til ..
4
28 okt
NOVO-B
Det er herligt at man kan købe massivt ind til pensionsporteføljen, samt de frie midler for kvalitet..
4
30 okt
NOVO-B
Ja, hun får sikkert også rollen i næste Star Wars, fandt lige dette billede på nettet, det er da svæ..
3
28 okt
NOVO-B
Sommerudsalg....... Det er en OUTLET butik iøjeblikket. Dem der får billige Novoer bliver lykkelige ..
3
28 okt
NOVO-B
Egentlig burde Novo stige når de andre sælger mindre, for mænden af insulin der sælges er vel konsta..
3

SAS: Ryanair-boss forudser konkurrenters kollaps

31-10-2014 15:26:57
SAS er blandt en række flyselskaber, som Ryanairs topchef, Michael O'Leary, venter vil skrumpe eller indgå i fusion med andre selskaber inden for de næste fem å..

GN går glip af Siemens høreapparater - bureau - NY

31-10-2014 13:47:16
Ifølge rygter skulle den svenske kapitalfond EQT have de bedste chancer for at overtage høreapparatdivisionen fra Siemens.Det skriver Reuters med henvisning til..

Aktier/middag: På vej mod forsigtigt punktum på solid uge

31-10-2014 11:35:58
Efter en stærkt positiv start på fredagens danske aktiehandel er investorerne igen gået ned i et lavere, men tilsyneladende meget stabilt gear. Dermed peger det..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
SAS: Ryanair-boss forudser konkurrenters kollaps
2
Veloxis ender som aktiebundprop - investorer taber 1 mia.
3
GN går glip af Siemens høreapparater - bureau - NY
4
Vestas får tyrkisk ordre på 66 megawatt
5
Fredagens aktier: Bank of Japan bankede C20 tilbage mod toppen

Relaterede aktiekurser

Novo Nordisk B A/S 268,70 -1,0% Fald i aktiekurs
Novo-Nordisk A/S 45,18 -2,2% Fald i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Relaterede selskaber
Få adgang til information og anbefalinger af relaterede selskaber med PLUS pakken.

Du får adgang til 7 værdifulde investorværktøjer til investering.

Klik her og læs mere om PLUS pakken.
Euroinvestor i andre lande: Euroinvestor.com | Euroinvestor.se | Euroinvestor.no | Euroinvestor.fr | Forexinvestor.com| Wisselkoersen.nl | Valuta.se | Valutaveksel.no | Divisas.es | Valute.it
Copyright Euroinvestor A/S 2014  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
1. november 2014 13:32:21
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20141028.2 - EUROWEB7 - 2014-11-01 13:32:21 - 2014-11-01 13:32:21 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x